Effects of Rifampicin on the Pharmacokinetics of BI 425809 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs BI 425809 (Primary) ; Rifampicin
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 21 Jun 2017 Status changed from active, no longer recruiting to completed.
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2017 Status changed from not yet recruiting to recruiting.